<SEC-DOCUMENT>0001564590-20-046215.txt : 20201009
<SEC-HEADER>0001564590-20-046215.hdr.sgml : 20201009
<ACCEPTANCE-DATETIME>20201009170032
ACCESSION NUMBER:		0001564590-20-046215
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20201007
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201009
DATE AS OF CHANGE:		20201009

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		201233800

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>arwr-8k_20201007.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-10-09T15:26:06.8551238+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 57e68f760d9948359a036473f6407885 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:arwr="http://www.arrowheadresearch.com/20201007" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
arwr-8k_20201007.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000879407_20201007_20201007">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000002" name="dei:EntityCentralIndexKey" contextRef="C_0000879407_20201007_20201007">0000879407</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="arwr-20201007.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000879407_20201007_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-07</xbrli:startDate>
					<xbrli:endDate>2020-10-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;margin-bottom:0pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:38.6%;margin-right:38.46%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000003" name="dei:DocumentType" contextRef="C_0000879407_20201007_20201007">8-K</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:38.6%;margin-right:38.46%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000004" name="dei:DocumentPeriodEndDate" contextRef="C_0000879407_20201007_20201007" format="ixt:datemonthdayyearen">October 7, 2020</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:38.6%;margin-right:38.46%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000000" name="dei:EntityRegistrantName" contextRef="C_0000879407_20201007_20201007">Arrowhead Pharmaceuticals, Inc.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:38.6%;margin-right:38.46%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:34%;"></td>
<td style="width:1%;"></td>
<td style="width:32%;"></td>
<td style="width:1%;"></td>
<td style="width:32%;"></td>
</tr>
<tr>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000879407_20201007_20201007" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000879407_20201007_20201007">001-38042</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000879407_20201007_20201007">46-0408024</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityAddressAddressLine1" contextRef="C_0000879407_20201007_20201007">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine2" contextRef="C_0000879407_20201007_20201007">Suite 700</ix:nonNumeric>, <ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000879407_20201007_20201007">Pasadena</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000879407_20201007_20201007">CA</ix:nonNumeric> <ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000879407_20201007_20201007">91105</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices) (Zip Code) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000879407_20201007_20201007">626</ix:nonNumeric>)&#160;<ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000879407_20201007_20201007">304-3400</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:38.6%;margin-right:38.46%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4%;"></td>
<td style="width:96%;"></td>
</tr>
<tr>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000879407_20201007_20201007" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-24pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
<tr>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000879407_20201007_20201007" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-24pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td>
</tr>
<tr>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000879407_20201007_20201007" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-24pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) </p></td>
</tr>
<tr>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000879407_20201007_20201007" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-24pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4 (c)&#160;under the Exchange Act (17 CFR 240.13e-4(c) </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000019" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000879407_20201007_20201007" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a)&#160;of the Exchange Act. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:105.96%;">
<tr>
<td style="width:35.66%;"></td>
<td style="width:3.95%;"></td>
<td style="width:27.22%;"></td>
<td style="width:4.51%;"></td>
<td style="width:34.62%;"></td>
</tr>
<tr style="height:17.05pt;">
<td colspan="5" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.6pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.8pt;;text-indent:-0.8pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr style="height:14.9pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0000879407_20201007_20201007">Common Stock, Par Value $0.001 per share</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:TradingSymbol" contextRef="C_0000879407_20201007_20201007">ARWR</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:SecurityExchangeName" contextRef="C_0000879407_20201007_20201007" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:105.96%;"><tr><td></td></tr></table></div>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:105.96%;">
<tr>
<td style="width:10.6%;"></td>
<td style="width:95.36%;"></td>
</tr>
<tr>
<td style="width:10.6%;"></td>
<td style="width:95.36%;"></td>
</tr>
<tr style="height:9.9pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.01</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entry into a Material Definitive Agreement.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Exclusive License and Co-Funding Agreement</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 7, 2020, Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into an Exclusive License and Co-Funding Agreement (the &#8220;Agreement&#8221;) with Takeda Pharmaceuticals U.S.A, Inc., a Delaware corporation (&#8220;Takeda&#8221;).&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Agreement, Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate <span style="color:#000000;">being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency (AATD), which is a rare genetic disorder that severely damages the liver and lungs of affected individual</span>. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with the Company eligible to receive tiered royalties of 20 to 25% on net sales.&#160;&#160;The Company will receive $300 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740 million.&#160;&#160;&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The transactions contemplated under the Agreement are subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The description of the Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01. Financial Statements and Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;Exhibits </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:8.37%;"></td>
<td style="width:6.61%;"></td>
<td style="width:85.02%;"></td>
</tr>
<tr>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex991_34.htm"><span style="text-decoration:underline;">Press Release, dated October 8, 2020.</span></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: October 9, 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:right;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td style="width:3.1%;"></td>
<td style="width:0.53%;"></td>
<td style="width:36.37%;"></td>
</tr>
<tr>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD PHARMACEUTICALS, INC.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kenneth Myszkowski</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kenneth Myszkowski</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>arwr-ex991_34.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex991_34.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Century;font-size:10.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn1ra4fhlkjg000001.jpg" title="" alt="" style="width:185px;height:55px;"><font style="margin-left:41pt;"><img src="gn1ra4fhlkjg000002.jpg" title="" alt="" style="width:165px;height:55px;"></font><font style="font-family:Verdana;text-transform:uppercase;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Century;font-size:10.5pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit 99.1
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:18pt;font-family:Gotham Medium;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">News Release</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:18pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease</p>
<p style="line-height:17pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.36%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8722;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS PMincho;font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.36%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8722;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS PMincho;font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.36%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8722;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS PMincho;font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda and Arrowhead under a 50/50 profit-sharing structure</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.36%;white-space:nowrap">
<p style="line-height:17pt;text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8722;</font></p></td>
<td valign="top">
<p style="line-height:17pt;text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS PMincho;font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Takeda receives exclusive license to commercialize ARO-AAT outside the U.S. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.36%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8722;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS PMincho;font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Arrowhead will hold a conference call and webcast today, Oct. 8, at 8:30 a.m. ET</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:4.36%;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="line-height:18pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Osaka, JAPAN, and Pasadena, CALIF., October 08, 2020 &#8211;<font style="font-weight:normal;"> </font><font style="text-decoration:underline;font-weight:normal;">Takeda Pharmaceutical Company Limited</font><font style="font-weight:normal;"> </font><font style="letter-spacing:0.5pt;font-weight:normal;">(</font><font style="letter-spacing:0.5pt;text-decoration:underline;font-weight:normal;">TSE:4502/NYSE:TAK</font><font style="letter-spacing:0.5pt;font-weight:normal;">)</font><font style="font-weight:normal;"> (&#8220;Takeda&#8221;) and Arrowhead Pharmaceuticals Inc.&#160;(NASDAQ: ARWR)&#160;today announced a collaboration and licensing agreement to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD). ARO-AAT is a potential first-in-class therapy designed to reduce the production of mutant alpha-1 antitrypsin protein, the cause of AATLD progression.</font></p>
<p style="line-height:18pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="line-height:18pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, Takeda and Arrowhead will co-develop ARO-AAT which, if approved, will be co-commercialized in the United States under a 50/50 profit-sharing structure. Outside the U.S., Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with Arrowhead eligible to receive tiered royalties of 20-25% on net sales. Arrowhead will receive an upfront payment of $300 million and is eligible to receive potential development, regulatory and commercial milestones up to $740 million. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S. </p>
<p style="line-height:18pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;AAT-associated liver disease is a devastating condition for which there are no approved therapies. With its RNAi-based mechanism&#160;of action, ARO-AAT has the potential to treat the underlying cause of AATLD, thereby helping patients&#160;avoid&#160;the need for liver transplantation and associated co-morbidities,&#8221;&#160;said Asit Parikh, M.D., Ph.D., Head, Gastroenterology Therapeutic Area Unit at Takeda. &#8220;We are excited to collaborate&#160;with Arrowhead to bring forward this exciting late-stage liver asset for the Alpha-1 community as part of our growing GI portfolio.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.18%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda&#8217;s global</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> presence</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">experience with payers and regulators </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the rare disease </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GI </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therap</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y space, combined with</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">long </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">history serving</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Alpha-1 community </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">make </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ideal partner for ARO-AAT. It is</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">well-positioned to </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">work with </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the patient and medical community </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to help meet </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the severe unmet need</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of patients with Alpha-1 liver disease</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;&#160;said Christopher Anzalone, Ph.D.,&#160;President and CEO&#160;at Arrowhead.&#160;&#8220;This agreement also </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supports our strategy of using partnering selectively </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> continue to </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invest in </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Targeted RNAi Molecule (TRiM</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) platform and</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the growing </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pipeline </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of RNAi therapeutics targeting diverse </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tissue types, while focu</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sing our </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> organization on opportunities</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in two key areas of cardiometabolic and pulmonary</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Alpha-1 Antitrypsin-Associated Liver Disease</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alpha-1 Antitrypsin-Associated Deficiency (AATD) is a rare genetic disorder associated with liver disease in children and adults and pulmonary disease in adults. AATD is estimated to affect 1 per 3,000-5,000 people in the United States and 1 per 2,500 in Europe. The protein AAT is primarily synthesized and secreted by liver hepatocytes. Its function is to inhibit enzymes that can break down normal connective tissue. The most common disease variant, the Z mutant, has a single amino acid substitution that results in improper folding of the protein. The mutant protein cannot be effectively secreted and accumulates in globules inside the hepatocytes. This triggers continuous hepatocyte injury, leading to fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individuals with the homozygous PiZZ genotype have severe deficiency of functional AAT leading to pulmonary disease and liver disease. Lung disease is frequently treated with AAT augmentation therapy. However, augmentation therapy does nothing to treat liver disease, and there is no specific therapy for hepatic manifestations. There is a significant unmet need as liver transplant, with its attendant morbidity and mortality, is currently the only available cure.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About ARO-AAT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin (Z-AAT) protein, the cause of progressive liver disease in AATD patients. Reducing production of the inflammatory Z-AAT protein is expected to halt the progression of liver disease and potentially allow it to regenerate and repair.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Takeda in Gastroenterology</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that GI and liver diseases are not just life disrupting conditions, but diseases that can impact a patient&#8217;s quality of life.<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup><sup style="font-size:85%;line-height:120%;vertical-align:top">,</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> Beyond a fundamental need for effective treatment options, we understand that improving patients&#8217; lives also depends on their needs being recognized. With nearly 30 years of experience in gastroenterology, Takeda has made significant strides in addressing GI patient needs with treatments for inflammatory bowel disease (IBD), acid-related diseases, short bowel syndrome (SBS), and motility disorders.<font style="color:#FF0000;"> </font>We are making significant strides toward closing the gap on new areas of unmet needs for patients who have celiac disease, <font style="Background-color:#FFFFFF;">eosinophilic esophagitis,</font> alpha-1 antitrypsin-associated liver disease,<font style="font-size:10pt;font-family:Arial;"> </font>Crohn&#8217;s disease, and acute pancreatitis, among others. Together with researchers, patient groups and more, we are working to advance scientific research and clinical medicine in GI. </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Century;font-size:10.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.18%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="line-height:18pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Conference Call and Webcast </font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Information</font></p>
<p style="line-height:18pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors may access a live audio webcast on the Company's website at <font style="text-decoration:underline;">http://ir.arrowheadpharma.com/events.cfm</font>. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 1790033.</p>
<p style="line-height:18pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="line-height:18pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk52544484"></a><a name="_Hlk52544484"></a>A replay of the webcast will be available on the company&#8217;s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 1790033.</p>
<p style="line-height:18pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;letter-spacing:0.5pt;font-style:normal;text-transform:none;font-variant: normal;">About Takeda Pharmaceutical Company Limited</p>
<p style="line-height:17pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;letter-spacing:0.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda Pharmaceutical Company Limited (<font style="text-decoration:underline;">TSE:4502/NYSE:TAK</font>) is a global, values-based, R&amp;D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&amp;D efforts on four therapeutic areas:<font style="font-family:Century;font-size:10.5pt;"> </font>Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&amp;D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&amp;D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.</p>
<p style="line-height:17pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;letter-spacing:0.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information, visit <font style="text-decoration:underline;">https://www.takeda.com</font><font style="font-family:Century;font-size:10.5pt;">.</font></p>
<p style="line-height:17pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Important Notice</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purposes of this notice, &#8220;press release&#8221; means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, &#8220;Takeda&#8221; is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; are also used to refer to subsidiaries in general or to those </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Century;font-size:10.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.18%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Takeda Forward-Looking Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda&#8217;s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as &#8220;targets&#8221;, &#8220;plans&#8221;, &#8220;believes&#8221;, &#8220;hopes&#8221;, &#8220;continues&#8221;, &#8220;expects&#8221;, &#8220;aims&#8221;, &#8220;intends&#8221;, &#8220;ensures&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, &#8220;could&#8221; &#8220;anticipates&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221; or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda&#8217;s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda&#8217;s operations and the timing of any such divestment(s); and other factors identified in Takeda&#8217;s most recent Annual Report on Form 20-F and Takeda&#8217;s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda&#8217;s website at: <font style="text-decoration:underline;">https://www.takeda.com/investors/reports/sec-filings/</font> or at <a href="http://www.sec.gov/Archives/edgar/data/1395064/000139506419000005/0001395064-19-000005-index.htm"><font style="text-decoration:underline;">www.sec.gov</font></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda&#8217;s future results. </font></p>
<p style="line-height:17pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About&#160;Arrowhead Pharmaceuticals</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals&#160;develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit&#160;<font style="text-decoration:underline;">www.arrowheadpharma.com</font>, or follow us on Twitter&#160;<font style="text-decoration:underline;">@ArrowheadPharma</font>. To be added to the Company's email list and receive news directly, please visit&#160;<font style="text-decoration:underline;">http://ir.arrowheadpharma.com/email-alerts</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Safe Harbor Statement under the Private Securities Litigation Reform Act:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Century;font-size:10.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.18%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Century;font-size:10.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.18%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.9%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #FFFFFF; border-right:solid 0.75pt #FFFFFF;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Takeda Media Contacts:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #FFFFFF; border-right:solid 0.75pt #FFFFFF;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japanese Media</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kazumi Kobayashi</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">kazumi.kobayashi@takeda.com</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+81 (0) 3-3278-2095</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media outside Japan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chris Stamm</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">chris.stamm@takeda.com</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 (617) 374-7726 <font style="font-family:Century;font-size:10pt;"> </font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Investor Contacts:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vince Anzalone, CFA<br />626-304-3400<br /><font style="text-decoration:underline;">ir@arrowheadpharma.com</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OR</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Media Contacts:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LifeSci Communications, LLC<br />Josephine Belluardo, Ph.D.<br />646-751-4361<font style="font-weight:bold;"><br /></font><font style="text-decoration:underline;">jo@lifescicomms.com</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LifeSci Advisors, LLC<br />Brian Ritchie<br />212-915-2578<br /><font style="text-decoration:underline;">britchie@lifesciadvisors.com</font></p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># # #</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">References: </p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup></font></p></td>
<td valign="top" style="width:98.13%;">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Bookman Old Style;"> </font><font style="font-size:11pt;">Center for Drug Evaluation and Research (CDER) &amp; the FDA. The Voice of the Patient/Functional Gastrointestinal Disorder; 2016. https://www.fda.gov/media/95140/download</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></font></p></td>
<td valign="top" style="width:98.13%;">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Bookman Old Style;"> </font><font style="font-size:11pt;">Jones R, et al. Management of common gastrointestinal disorders: quality criteria based on patients&#8217; views and practice guidelines. Br J Gen Pract. 2009; 59(563):e199-208.</font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Century;font-size:10.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gn1ra4fhlkjg000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn1ra4fhlkjg000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0'217AI9@  34T *@    @ #0$   ,
M   !!P@   $!  ,    ! E@   $"  ,    $    J@$#  ,    !  $   $&
M  ,    !  (   $1  0    B    L@$2  ,    !  $   $5  ,    !  0
M  $6  ,    ! !(   $7  0    B   !.@$<  ,    !  $   %2  ,    !
M  $   %3  ,    $   !P@      "  (  @ "     @  ?I(  /TB  %[L@
M!^D(  GC2  +W8@ #=?(  _2"  1S$@ $\:( !7 R  7NP@ &;5( !NOB  =
MJ<@ 'Z0( "&>2  CF(@ )9+( ">-"  IAT@ *X&( "U[R  O=@@ ,7!( #-J
MB  U9,@ -U\( #E92  [4X@ /4W( #](" !!0D@  ?I   'Z0  !^D   ?I
M  'Z0  !^D   ?I   'Z0  !^D   ?I   'Z0  !^D   ?I   'Z0  !^D
M ?I   'Z0  !^D   ?I   'Z0  !^D   ?I   'Z0  !^D   ?I   'Z0  !
M^D   ?I   'Z0  !^D   ?I   'Z0  !^D   *C   $  0 !  '_X@Q824-#
M7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M  !A8W-P35-&5     !)14,@<U)'0@                  ]M8  0    #3
M+4A0("
M         !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B
M:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0
M !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #
MU    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER
M:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M       2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q
M.38V+3(N,0
M                6%E:(        /-1  $    !%LQ865H@
M         %A96B        !OH@  ./4   .06%E:(        &*9  "WA0
M&-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                          !D
M97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(
M9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$
M '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M $P)5@!0    5Q_G;65A<P         !                         H\
M   "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H
M "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4
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M,C(R,C(R,C+_P  1" )8!P@# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1534W:/2;QT8JRP.58'!!VGFO'/[=UC_H*WW_ ($/_C2;L-*Y
M[=17B/\ ;NL?]!6^_P# A_\ &O9[)F:QMV8DL8E))/)XH3N#5B>BBBF(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!X+/_Q\2?[Y_G4=23_\?$G^^?YU'69H>S>%O^17T_\ ZY#^=;%8_A;_
M )%?3_\ KD/YUL5H9A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /!9_^/B3_?/\ZCJ2?_CXD_WS
M_.HZS-#V;PM_R*^G_P#7(?SK8K'\+?\ (KZ?_P!<A_.MBM#,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"GJW_(&OO^O>3_ -!->&U[EJW_ "!K[_KWD_\
M037AM3(J(5[M8_\ (/MO^N2_R%>$U[M8_P#(/MO^N2_R%$0D6****HD****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MPO%7B%- TLR+AKJ7*P(?7NQ]A_A6Q<7$5K;27$[A(HE+NQ[ 5XCK^LS:[JTM
MY)D)]V)/[B#H/Z_4UV8/#^VG=[(YL36]G&RW9G2RR3S/-*[/([%F9CDDFF44
M5[YY 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *]J\')Y?A+3EXYC)X]V)_K7BM>Z^'X_*\.::AZBVCS]=HKS,S?[
MM+S.W KWVR[<2>5;2R9QL0MGZ"OGVO=]<E\G0-1DS]VVD(^NTUX14Y8O=DRL
M<]8H****]4X HHHH **** "BBB@ KT_X91XT>\E_O7&W\E'^->85ZW\.XO+\
M+!L?ZR=V_D/Z5PY@[4?F=6#5ZIUE%%%>">L%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >"S_\?$G^^?YU'4D__'Q)_OG^
M=1UF:'LWA;_D5]/_ .N0_G6Q6/X6_P"17T__ *Y#^=;%:&84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %/5O^0-??\ 7O)_Z":\-KW+5O\ D#7W_7O)_P"@
MFO#:F140KW:Q_P"0?;?]<E_D*\)KW:Q_Y!]M_P!<E_D*(A(L44451(4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11574;Z
M+3=.N+V8_)"A8\]3V'XG _&FDV[(3=E=G#?$;7<;-&@;KB2XQ^:K_7\J\[J>
M\NI;Z\FNIVW2RN78^YJ"OI:%)4J:BCQ*M1U)N04445L9A1110 4444 %%%%
M!1110 4444 %%:VF>&M7U?#6MF_E'_EJ_P J?F>OX5UEE\,7(#7^H*#W2!,_
M^/'_  KGJ8FE3TDS6%"I/9'GM%>NV_P]T"$#?%//_P!=)2/_ $'%7!X+\/
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MMKVDRS1?)*BD2Q$Y*G'\O>O&ZNZ5JD^D7RW,![%73/#J>HJE0V"5@KV[0O\
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MB<N:384445H2%%%% !1110 4444 =?\ #FW\WQ(\I'$,#-GW) _D37K%>?\
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M]IO_ %Z1?^@"O$:]NT+_ )%[3?\ KTB_] %.(I&A1115$F!XV_Y%"^_[9_\
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M_CXD_P!\_P ZCJ2?_CXD_P!\_P ZCK,T"O4/"'A1--@2_O8PUZXRJL/]4/\
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M8HHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5+*05[=H7_(O:;_UZ1?^@"O$:]NT+_D7M-_Z](O_ $ 41"1H44451)@>-O\
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ME1_[S<?H,G\*V:\W^(NI>;?V^G(WRPKYCC_:/3\A_.DQK<XFG(C22+&@+,Q
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MK:\,ZY%H%]+=/;&=GC\M0'VXY!/;VJ2CV2BN$_X67#_T#'_[_#_"C_A9</\
MT#'_ ._P_P *JZ)LSNZ*X3_A9</_ $#'_P"_P_PH_P"%EP_] Q_^_P /\*+H
M+,[NBN$_X67#_P! Q_\ O\/\*/\ A9</_0,?_O\ #_"BZ"S.[HKA/^%EP_\
M0,?_ +_#_"C_ (67#_T#'_[_  _PHN@LSNZYSQO8"]\-S.!F2V(E7Z#@_H3^
M58__  LN'_H&/_W^'^%0W7Q#M[JTFMWTQ]LL;(?WPZ$8]*+H+,X*I[.X:SOH
M+E<[H9%<8]CFH**DL]]5@RAE.01D&EJCHLOG:'I\I.2UO&3]=HS5ZK,SRCQ[
M=FX\3/%GY;>-8Q]2-Q_G^E<Q6CK\OG^(=1?.<W#@?0' _E6=4,L[7X=:>)=0
MN+]QQ NQ/]YNOZ#]:])KEO %N(O#(DQS-,[Y^F%_I74U2V)>X4444Q!1110
M4444 %%%% %+5[!=4TFYLGQ^]0A2>S=0?P.*\/92K%6!# X(/:O?:\6\36XM
M?$NH1 8'G%P/][YOZU,BHF57H_PV_P"0???]=5_E7G%>C_#;_D'WW_75?Y4E
MN-[';U6U"Y%EIUS='_EC$S_D,U9K"\93>3X4OB#RRJ@_%@/Y59!X^S%F+,<D
MG)/K245-:0_:;V"#_GI(J?F<5!H>O>%-/&G>'+2/;B21?-D^K<_H,#\*VJ0
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ME&/17=_\*TF_Z"<?_?D_XT?\*TF_Z"<?_?D_XT6871PE%=W_ ,*TF_Z"<?\
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M>3^"M;&E:MY,[;;:ZPC$]%;^$_KC\?:O6*I$M!1113$%%%% !1110 444A(
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M_9TVSSDDL2222>23WI***^D/$/?[#G3K4G_GDG\A5BJ6DDG1K$DY)MXR2?\
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M0!X7J&G76F7;6UY"T<@]>A'J#W%5:]QU+2K+5K8P7L"R+_">C*?4'M7 :O\
M#Z]MF:339!<Q=1&Q"N/Z']/I4M%IG&U/;WMU9MNMKF:$GJ8W*_RIMQ:W%G*8
MKF"2&0?PR*5/ZU%2&;$?BK78_NZE,?\ >PW\Q3)?$VMS AM3N1G^Z^W^595%
M A\LLD\A>61Y'/5G8DTRBKMAI&H:F^VSM)9><;@N%'U)X% RE6QH/AR\UVX
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M **** (_(A_YY)_WR*/(A_YY1_\ ?(J2B@!  HPH  ["EHHH **** "BBB@
MHHHH 1E5QAE##T(IGD0_\\H_^^14E% #!#$#D1(".A"BGT44 %%%% !1110
M4444 1S00W$>R>))4/\ "ZAA^M8]QX/T&X.6T]$/K&S)^@.*W** .6;X?Z(Q
MX^TK])?\13H_ .AI]Z.=_P#>E/\ 3%=/12LAW9DVWAG1;0@PZ;!D="XWD?\
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MKW6+K[1?3M*_\(Z*H] .U4J*]2CAJ='X5KW.&K7G4W"BBBN@Q"BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZUV%>$V/_(0MO^NJ_P Q7NU),&K!1113$%%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.UK2(-;TR2RGXW<H^
M.4;L16C13C)Q=T)I-69X%J%A<:9?2V=TFR6-L'T/H1[&JM>Q>+_#"Z]9>;
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/'7ARV6R;5;2)8I(V'G*@P&!.,X]<_SIM"N9?@KQ)+97L>FW,A:TF;;'N/\
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M*"".1Q4]%4E8ENYYI\2/^0S:?]>__LQK/\"_\C7;?[C_ /H)K0^)'_(9M/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK$=[HZV+O_I%J,;3U9,\'\.GX"NKJD2PHHI RMG!!P<'!Z&@!:\E\=DGQ5<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC1D0V$,;]F9RP'X<5FW'@/787VQP13K_ 'HY5'_H6*=:> M;GDQ-'%;+W9Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% !1110 4444 %%%% !6/XI_P"17U#_ *Y'^=;%8_BG_D5]0_ZY'^=
M'C->W:%_R+VF_P#7I%_Z *\1KV[0O^1>TW_KTB_] %3$J1H44451(4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !534[$:EIEQ9&0QB9-NX#
M.*MT4 <)_P *TA_Z";_]^1_C79V5L+*PMK4-O$$2QAL8SM &?TJQ12L.X444
M4Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gn1ra4fhlkjg000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn1ra4fhlkjg000001.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_[@ .061O8F4 9      !_^$ 2D5X:68
M $U- "H    (  ,!&@ %     0   #(!&P %     0   #H!*  #     0 "
M         ,@    !    R     $  /_B#%A)0T-?4%)/1DE,10 ! 0  #$A,
M:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%
M0R!S4D="                  #VU@ !     -,M2% @(
M                                                $6-P<G0   %0
M    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H
M  (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M
M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X
M%&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\
M   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE
M=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q
M.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                      !865H@
M        \U$  0    $6S%A96B                      6%E:(
M &^B   X]0   Y!865H@        8ID  +>%   8VEA96B         DH
M#X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M       6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                     &1E<V,         +DE%0R V
M,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M        +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E
M("T@<U)'0@                            !D97-C         "Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M       L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V
M+3(N,0                                  =FEE=P      $Z3^ !1?
M+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M          $                        "CP    )S:6<@     $-25"!C
M=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/
M %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P
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M6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@ , P$
M A$#$0 _ -_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M]V%\AN@NI?*.U.\.H>M6A"M*F_NR=F[0D0/)X8[Q[@S./DO),-"BUV?TBYX]
ME&X<P;#M-?WI>VEM3_?LT<?_ !]AY]2+RA[0>[/N#I/(?*_,.]!C@V&W7EV#
M05.;>&08&3Z#)QT3W=W\WS^6SLGR?QGY9]>5OCU:O[HT&\M_WT_;W\?]P]L;
MD\M_N5MIO>SV_P V^D(7?NW[<67]MNUNU/\ ?8DE]/\ ?2/Z_P"'T/617+W]
MWA]]+F:G[M]O]XCU?\I<EG8<=7'ZZYMJ?">-*=M?C6H#YO\ GZ?RTL5Y?L.U
M]Z[F\=1X$_@G478<'W$7K_RR+^\>"V_:G](XDT2^H>CZV(I_?CVVBKX=U-+0
MT[8)17Y]ZIC[:'Y=2MMG]TU]]>_T_5;!MEEJ34?&W;;VTG'8?IY[CN^:ZDP>
M[A5-_P#00C_+E_YZ3MK_ -%9E/\ ZN]IO]?_ -N_]^7?_.!O\_1U_P FAOOD
M_P#*%R__ -S2+_H#K+3_ /"@S^7%-/!#)NSM2DCEFCCDJJCJO-M!3([JK5$Z
MTM14U30PJ=3"..20J#I5C8&R^_WMT6 ,MT 3Q,#4'S-"3^P$_+IN;^Z)^^7'
M$TB;?L,CJI(5=TA#,0*A5U*JU/ :F5:G+ 9Z%';W\\C^6)N K$?D>^"JG>55
MIMP]4]R8\:(HQ)Y6KTV!4XB))!<('J%D9A;3<BYG;^]WMG<8_>.AO1X+@?S\
M(K_.O0%W?^ZZ^_#M +CDP74  JUONFSR9)I01F_64D<21&5 -:X-#0;*_F(?
M!3L.:*EVI\N/C_5UU0YCIL;D>S]J[<RU7(#+=*3$[ER.(R56X6!F(CB8A!J_
M202)[+W!Y&W A;7=K N> ,R(Q^Q7*D\/(?/J#N9ON>_>HY/C:??O;WFZ.U05
M:2/;+JXB08R\MM'+&@[@*LPSV\01T;7#YO"[BQ]/EMOY?%YW%5:+)2Y/#U])
MD\?4QNJNKT];12STTR,C@@JQ!!!_/L5PSPW$8EMW5XCP92&!^PBHZQ]W';-R
MV>\?;]WMY[6_C-&BFC>*12#0AD<*P(((H0,CIT]N](>O>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[I%;_[)Z\ZHVW6;R[0WUL_KK:6/TBMW+OC<F'VM@J9G
MOXXY<KFZRBHEFE(LB:];MPH)X]HK_<MOVJV-YN<\-O:+Q>1U11_MF('0FY2Y
M+YPY^WJ/ESD;:MQWGF";X+:RMYKJ=@.)$4*.]!Q)I0#)('5*?R&_X4*?"#J2
M2NQ'5<6^/D9N2E\L4<FS<6VT]B"KA9D>GJ]Y;QBH:Z6$LHTU&-Q.4IY%-U<B
MUX8Y@^\!R3M):':Q/N-R/]]KHBKZ&22A_-$<'R/73'V@_N@_O/\ N"D6X\^-
MM?)NRO0D7DOU5]H-"&2SLRZ TXQW-U;2*<,H/"L"?^=+_-.^8^;JMK?"SXZT
M&U8#.:<9#8?7^5[@W#@9)8T9&W)O;>%&_6F*@B5E*RUF&HHM3C4QU*/<9-[R
M^Z'.$YM>3-N6):TK%$UPZ_Z>20>"H^;1J,Y\NLY(O[M/[B/W<=LCWW[R_.,M
M_+HU>'?7\6T6\X!-?IK*S<;E*Q-05AO)FHIT@48]";@_Y5G\XOY7!<A\N?FC
MF>K=N973-D-FU'9.Y-]5M'),BF33UKUQDL!U)'HCD9"(<NAU#3;3ZO9G![6^
M[_-7ZG-F\O:V[\8S,\I'_-F$K!^R3^70(W3[^7]W+[!DVGW>_;6VWW>8*B.\
M7;K:Q1P":5W+<8Y]V-2 1KM#@UKJQT:SJ[_A-I\0MM"&K[5[5[L[7RB@_<04
M-?MSKW;-4[MJ>5\9C\/G=RI)<>G3FK"[7#$@J*=L^[ERE;4?=+J]NI?, I$A
M_(*S_P#53J!.>O[Z/[P^]EK?D/8>6=@L2>UG2XW"Y4#@!))-!;$>M;.N!0@5
M!/CLC^3A_+6V"M/_  OXL[/S4\&AFJ=[Y[?&_FJ95,3&6HI=X;HS6-/D:($H
MD"16+ (%9@1U9>S_ +<6 'A;7"[#SD:66OVB1V'Y4I\NL4^:/[QW[ZG-C/\
M7<][C;1-6BV4%E8!1G"M9VL,F*X8N7X$L2 09'!?!SX6[9A\& ^(_P :,4IA
MA@EDI.C>LTJJF. -XOO*P[9:KK7343JF=V)))-R?8C@Y(Y-MAI@VG;4Q3%M#
M4T]3HJ?S)ZA?=?O1?>6WN3Q=V]P>=ISJ+ /O>Y%5+<="?4Z$!H,(JC %,="-
M3_'SH.D@@I:7I#J"FI::&.GIJ:GZUV9#!3P0HL<,$$,>%6.*&*-0JJH"JH
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M7+(=$%)1TT204U-$L=/2TT:0PI'$B(N$FX[E?[O?2;EN<KSWTS:G=S5B?\@
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M))!4%(0RQ:Z+)</#%75(H.C?_+!^,VX?YA?SVQE7VA+4;KVQB\_E^_N_\QE
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MQ37"UVK;],\OH6!_1C/^G<:B#@HCCKMK_>9_>.3V!^[=?;9L\PCY^YN$NU6
M![XX9(Z;C=@8(%O:OX2.IU1W-U;/D ];6G\T/^:=L/\ EZ[2Q. Q&)Q_8?R$
MWWC:C([(Z_JJN6#$8/")+/1+OG?LM%)'D(-N?Q*GD@I*2%X:G*SP31Q2Q)#/
M/#E-[G>Z%C[?VB00HMQS!.I,<1-%5<CQ9:9"5!"J*%R" 0%9AP2^XQ]Q'FO[
MWO,%QNVX7$VS^T.U3K'>WZH&EGF(5_H;$.#&UQX;*\LKAX[5'C>1)&DBBDU_
M/C=BOYOG\WO<NXNP(_DYOGISIC$9AL?D=UX?<>YNM>MJ7)QK#,NUMC;&Z\J<
M/+O7,8>DEC>66JD?[=64U5>)YD$L!\N1>[?NW<R7XW.>SV9'H75WAA#?P111
M%?$912I8X_')J(KUO]Z+_P#N\/[O'9+/E)^1]KYC]R;BW$D=K-;VVY;BT1J/
MJKV^W!9A90S.&"K$H\0@^!:&*-C&2?YC_(+^8G\8>PM[?"3L_P"7O:^Z(.F]
MY8K,4V=PV_=RIE<DN=V9CLQMJJCWQ-/3]@RX.IVENB"48>JR$M%25$ATQEXU
MD]@OG#?_ '"Y9W";DK<]WNI5LYE8,LKZCJC#(?$)$NDQN#X;,54GA45ZR:^[
MC[1?<[]\>4-L^\YR/[>;!8R\R;;+"T$UA;&*/P+R2&Y4V2JU@)UN[5U-W% D
MTL:BKZ7*=;8/\E;J'MC87PXP/:G>O8G8^^^P_D#)2]DHG8V\MT[H?:G7AI9(
MNOL7CH]S9*N7'C+X>>3-3R0B,S+DXXY-0IT(RJ]F=HW6PY/CW3?+BYGW#<")
MOUI'?1%3])1K)IJ4F0D4KK /PCK@1_>7^X?('-GWCKOD/VLV?9MJY0Y15MN)
MVZSM;476X:@=PED-M&GB>%,JV:*Y8(;9W2AF8'4A_FW_ #*;YG?,;?&Z<!E#
M7=3];&7J[J-892]!6;:V[6U(RF[:<*1%*=[[BDJ:^*8HLIQ[TD,E_ +8G>['
M./\ 7+G">ZMVU;5;?HP>A1"=4@_YJ/J8'CHT _#U]!G]WU]V\?=L^[EM>Q;M
M!X7/^]4W/=B11TN;A%\*T:N1]%;B.!DJ4^H%Q(G]J>K#,'_-9FZ'^/O3?P(_
ME:; SN].P6PM-B<]W;7[(J\EN/>':&YE?+[QRO575]325>1R-959RJE%+69^
MGD^TH8%IQCWCBBJ5D&#W3;8M@L^1/:^WDFW#0%:Y,9+R3/W2-!"0226)TM*#
MI4:?#( ;K$#=/N$Q>ZONYS)][#[]F[6NV<HBY:6#98[U([>TVRV(ALXMTW-7
M2.-%@5/%AL)%\6=S,;M7D> V"_ _^4'\A,MG*;OG^8=WYVYN3<N5KDW)%T3B
M^W]X5<,U?4$5;2]L[MQ>?T9"9*A_5A\1-]H/&HEK)HFDI0/^1?:3F"6<;[[@
MW]W)<LVOZ9;B0Y.?UY%?.?\ 0XSIP*N15>L1?O5_WA_M#M^UO[4_<^Y3Y>LM
ME@B-N=\EVBT0B->RFU6DL%8P5&+N[3Q>YC';1N$G)-OYKG\ZK?,>\-S_ !6^
M%&X_]'O7VPIGV7O'N+:$RT>X]RY/#*E!D-N=:92F1'VEM+;]33FD_B="R5M?
M+ QI9HJ,*U6#O=3WGOA=R\K<ER?3[? ?#DN(\.[+@I"P_LXT(TZU[F([2$R^
M1_W!O[L_E=^7;'WY^\U9?OCF[=E%Y9[1=C7;VT4U7CN-RB8D7=W<*PE^FG!A
M@5P)XY+FJVY:U_DX939GPK[-^;/S=[RRW4.Z9]E5V]-C]=S8M=P[ORVY,Q05
M$FR,-V'D<YD8*Q=V[ZW!4T<1Q<"M5T44Q:KGBF6>&F#@]GY;/DRYYTYUOGM+
MHPF2.+3KD9V!\-92Q!\25RHT#N4&KL#J"S4W]XY8<R_>7V3[LGW8N5K?F'8E
MW-+.]W 2FWM(K:&11>S;?'!&R&TL;=9F^JD(BF= MO%)&8I)Q$_X3:X?N"I^
M6'9V9VU59JEZ8Q?4F0I^T$,M5_=;);DR&:Q"]?4$M,&-%)NN.2#(5-),4\L-
M!!6H'59F60P^[E#N[<U7,UL7&S+:$3<=!<LOA"G#7ARIXA0XJ*T(._OHMQ]N
MH/8+8]MWI+:3W)GY@C;;#1?JH[:.&7Z^0-36+4AH(Y4KH>=[9BK&,,E\O\TW
M^:]LK^7[MW';+VGB<7V)\C]Z8F7*;7V;7U,B[=V=A&EDI*?>78/V%33Y1L=5
M5D4J4&/IW@GR34\W[]/&GE,Z^Z'NI9<@VZV=HBW',4R:DC)[(UX"26A#4)KI
M0$%Z'N4"O7*7[B7W!N9OO<;Q-S+S!<3[/[,[9<"*ZO(U'U%Y-0.UGM_B*T7B
M*A4SW$BNEN)(_P!*9VT"B'XR[*_F]_S<,MF>TZWY4=@=-=+T69GH#NN@W+N?
MKW8D^2IW45&$Z]ZXZYJMOP[MJ\!#((Y:RJ=(XVU1RU[U)D4P9RU9>[?NQ*^Z
M/NEQ9[,KD:P[Q1$CBL4,)3Q"O LU .!D+5'757WNYF_N\?[OG;[;D2VY#VCF
M3W*EMED^E>VMMPOEC8'3-N&X[BMP;1)R-2PQ!F84=+180C"M+YX]D?,[:&[]
MQ?"/Y/=^[G[DQ/Q\[#JZ_%'-YVHW33U>5R. I?X/N--RYNG;=^2AEVIEU-)3
M9&IF_AJUD\4:1L\NJ-N>MQYRM+N3DKF:_EO(MON"5U,7!8H-+ZV'B'L;M#DZ
M-3  5/6:_P!U/DO[MG,7+MG]YWV.Y2L>6]PYOV=$E\&!;5DBCG;QK<VT#?21
MD741$LEO&GU)AB=V<+'39X_E9]:]6?RO?Y<F9^5GR.K8]FY_N.BQ':.\IYZ7
MR[C3:]13RP=-=:83&EH:G([@RE!DWKXZ,B.2*OS4T<[)%3-)'DS[7[;M?MC[
M=OS3S$W@SWBK-(2._012WA4<2[!M07!#2$-0+4<//OV<Z\]_?F^^5;>PGLU$
M=RVGER27;+-5:EN;I6#;QN4TF5CMXI(Q TP+*T%E&\09Y@CU.;T_FE?S+?YF
M'>\/1OPU.;Z9V_GI*IL)M3K;(T^(W/C=L4,RK6;U[)[BEBI\O@X*"*K3[F7'
M38NB1GAIXH:BJ:-IXIO?<_W(]R=]&Q\G:[.WD)TI"0KA <R37&&4"N2A1>"@
M,Q&K/WEK[BGW*?N3>U3>Z7WD/I>9-WM%7QKK<8VFMI+EU[+/;MH!:&=I"A\-
M;A+F8@23/)# KB+)\TL1_-F_E<8+9>X-Y_.[?';&W^\\'O+862E?L7?O8--M
MG-#"1QY&DH(.V(JRLQ5<<?EC4XG-XM:2MBJ*1RXIRL0FWSG%[K>V$$-Q>;[/
M=V]\DD1_6EE"-IR )ZE31JI(FE@5-=-!6GW:=P^X!]^G==RVCEOVJVO8-WY6
MNK.^C VZQL&N8?&)C>1MJ*)*GB1>'=65T986CE4*9@S^&+G\@7;GR4^1OR#W
M7W=VCW?WINKJ+HC#FFI</N7M3?N6VUNKM#=U+4T6%QE?C,GGI\?FJ+;.WOO,
MC41,KB"L;'LXTR+J-O86WYDYBW^7>]TO;Z7:;%*!7GE9'FD!"J59B&")J<C-
M&\,GCU'W][3O/LM[->T5A[8<B\K\K6'N'S5<ZFFMMKL(KFUVRT97FECEB@62
M%[FX\&WC8$>)$+Q5-4--P#.X+"[GPN7VWN3$8W/[>S^-K<-G,'F:*FR6(S&(
MR5-)1Y'&9/'5D<U)78^NI)GBFAE1HY(V*L""1[RYG@AN87MKE%DMY%*LK %6
M4BA5@<$$8(.".OG;VO=-SV/<[?>MEN)K3=[29)H)X7:.6&6-@\<L4B$.DB.
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M9>O?\![_ '2_IR?_ ./G?_\ >^Z]_P .(?S^?]7\AO\ TBKK_P#^Y_\ ?O\
M7"]^O^DA_P!RZ+_MEZ]_P'O]TOZ<G_\ CYW_ /WONO?\.(?S^?\ 5_(;_P!(
MJZ__ /N?_?O]<+WZ_P"DA_W+HO\ MEZ]_P ![_=+^G)__CYW_P#WONO?\.(?
MS^?]7\AO_2*NO_\ [G_W[_7"]^O^DA_W+HO^V7KW_ >_W2_IR?\ ^/G?_P#>
M^Z]_PXA_/Y_U?R&_](JZ_P#_ +G_ -^_UPO?K_I(?]RZ+_MEZ]_P'O\ =+^G
M)_\ X^=__P![[KW_  XA_/Y_U?R&_P#2*NO_ /[G_P!^_P!<+WZ_Z2'_ '+H
MO^V7KW_ >_W2_IR?_P"/G?\ _>^Z]_PXA_/Y_P!7\AO_ $BKK_\ ^Y_]^_UP
MO?K_ *2'_<NB_P"V7KW_  'O]TOZ<G_^/G?_ />^Z]_PXA_/Y_U?R&_](JZ_
M_P#N?_?O]<+WZ_Z2'_<NB_[9>O?\![_=+^G)_P#X^=__ -[[KW_#B'\_G_5_
M(;_TBKK_ /\ N?\ W[_7"]^O^DA_W+HO^V7KW_ >_P!TOZ<G_P#CYW__ 'ON
MO?\ #B'\_G_5_(;_ -(JZ_\ _N?_ '[_ %PO?K_I(?\ <NB_[9>O?\![_=+^
MG)__ (^=_P#][[KW_#B'\_G_ %?R&_\ 2*NO_P#[G_W[_7"]^O\ I(?]RZ+_
M +9>O?\  >_W2_IR?_X^=_\ ][[KW_#B'\_G_5_(;_TBKK__ .Y_]^_UPO?K
M_I(?]RZ+_MEZ]_P'O]TOZ<G_ /CYW_\ WONO?\.(?S^?]7\AO_2*NO\ _P"Y
M_P#?O]<+WZ_Z2'_<NB_[9>O?\![_ '2_IR?_ ./G?_\ >^ZPU&UOY^GSF0;;
MW+3_ "DBVOG"4R,>Z:2F^-'7U?CZI'DEERE :+K#!Y_#B&["%*:L5B L4;/H
M4U:U]^.=Q]-<C=!:OQU@6<1!_B%(5=?E1OD":=.0[[_=-?=;;]\[(_(K;Y:Y
MC-J[<R7\<BD ")]>YSP35H-9DA(R7=5U'JT7X+?\)WMB];97!=E_,[<^&[:W
M)C9H,E0],;26L_T74=;%^[3_ -],]D8*#,;]2"0HSX^.EQ^-,L1CG;(4SLC2
M?R/]WRQVV5-RYRE2[N5((MXZ^"#Y>(Q :6GF@5$J*-XBFG6#'WIO[X7FKG2P
MNN2ONV6-SR_LTRM&^\W93]YNAPWT<$;20V)85"W#2W%P%8/$+2=0PV9*.CI,
M?24M!04M/0T-#3P4=%14<$5-24=)31+#34M+30JD-/3T\**B(BA44   #WDF
MB)&@CC 5%   %  ,  #@!Y#KB5<7%Q>7$EW=R/+=2NSN[L6=W8EF9F8DLS$D
MLQ)))))KU(]VZ9Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
*[]U[KWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>arwr-20201007.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-10-09T15:26:06.8551238+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 57e68f760d9948359a036473f6407885 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:arwr="http://www.arrowheadresearch.com/20201007" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20201007" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.arrowheadresearch.com/20201007/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20201007_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20201007_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>arwr-20201007_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-10-09T15:26:06.8551238+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 57e68f760d9948359a036473f6407885 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>arwr-20201007_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-10-09T15:26:06.8551238+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 57e68f760d9948359a036473f6407885 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20201007/role/TemplateLink" xlink:href="arwr-20201007.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="arwr-20201007.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>arwr-8k_20201007_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="arwr-20201007.xsd" xlink:type="simple"/>
    <context id="C_0000879407_20201007_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000879407_20201007_20201007" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000879407_20201007_20201007" id="F_000002">0000879407</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000879407_20201007_20201007" id="F_000003">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000879407_20201007_20201007" id="F_000004">2020-10-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000879407_20201007_20201007" id="F_000000">Arrowhead Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000879407_20201007_20201007" id="F_000005">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000879407_20201007_20201007" id="F_000006">001-38042</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000879407_20201007_20201007" id="F_000007">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000879407_20201007_20201007" id="F_000008">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0000879407_20201007_20201007" id="F_000009">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0000879407_20201007_20201007" id="F_000010">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000879407_20201007_20201007" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000879407_20201007_20201007" id="F_000012">91105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000879407_20201007_20201007" id="F_000013">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000879407_20201007_20201007" id="F_000014">304-3400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000879407_20201007_20201007" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000879407_20201007_20201007" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000879407_20201007_20201007" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000879407_20201007_20201007" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000879407_20201007_20201007" id="F_000019">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="C_0000879407_20201007_20201007" id="F_000020">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000879407_20201007_20201007" id="F_000021">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000879407_20201007_20201007" id="F_000022">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571188276072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arrowhead Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  07,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M]T!8'0[9AQLCL^)@NY0&CLG%I3V-<64'P/<K*<W[C3TKES]UC/X%4$L#!!0
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    (  ^(25&C\Q.8[P   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  ^(
M25&97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ #XA)4<!+34)>!   ]A   !@
M ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  ^(
M25&#J:4#U $  #(&   -              "  :(,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ #XA)49>*NQS     $P(   L              ( !H0X
M %]R96QS+RYR96QS4$L! A0#%     @ #XA)41PX9>H_ 0  / (   \
M         ( !B@\  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  ^(25$D
M'INBK0   /@!   :              "  ?80  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    (  ^(25%ED'F2&0$  ,\#   3
M      "  =L1  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' "43      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="arwr-8k_20201007.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="arwr-8k_20201007.htm">arwr-8k_20201007.htm</File>
    <File>arwr-20201007.xsd</File>
    <File>arwr-20201007_lab.xml</File>
    <File>arwr-20201007_pre.xml</File>
    <File>arwr-ex991_34.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arwr-8k_20201007.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "arwr-8k_20201007.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20201007_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20201007_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "arwr-20201007.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20201007",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "arwr-8k_20201007.htm",
      "contextRef": "C_0000879407_20201007_20201007",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "arwr-8k_20201007.htm",
      "contextRef": "C_0000879407_20201007_20201007",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20201007/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001564590-20-046215-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-046215-xbrl.zip
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M*D+8BN*!'\5^.[;L%]C8UZ_R06^+4FH&Q;.1L)30A&S/BI 9=Z/2% VK?R#
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MJ>(N< 4!0WT6GKPA;IBC$G&!W!;BDY$T,\0IP^X87;N]8EZ+JP% I <E&#[
M*1#O7Q^&N9P]4[0P?3CCQO%NG G$/.80XI'"J;P?IC333<31$W'8QR*.-S*T
M8+W@]<#0?(&Y*N;>H=["0&VTFX"J [Z'%!'ORE<LLARVF>!'@4,5JYX'K'H
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M1U @?0:Q^6J(Z #GTVJGLS!!LDJ0R*9G,N154#H-2KZ")09(H5/%]=D^-;^
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MV8,@S^IS6X^ 68#U/'NL6#D,1@[\^ ]02P,$%     @ #XA)48U3WH\"(0
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MNG<&]%4K4T?F^=6=TP4L #*'R817TL[:=Z<J!QH#<F<#J0W27#.,N3$L'PE
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M*N5ZLF(3"%8,GC)CPT)U_W'J9;TCKD@*_9(3Y0_[JLAOT\WCRTZD^\C$C\5
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MP59(L3C GMY@/1MN9:VG%V[]O*TJ'X:XO0-&H/40"G_P-,X;;:L8N\X7%JL
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M;P+V7+.?V \B9:?X:P!,IKUWP'I[Z[WMS8U]T=G#8UIV@VMQDR\] 7A[Q1*
MG[7Z*II@'G!KE"<Q?/A_4$L! A0#%     @ #XA)49TFM_V\!   X18  !$
M             ( !     &%R=W(M,C R,#$P,#<N>'-D4$L! A0#%     @
M#XA)4?#U$DLW!P  A4P  !4              ( !ZP0  &%R=W(M,C R,#$P
M,#=?;&%B+GAM;%!+ 0(4 Q0    (  ^(25'H)U9,$ 4  ,(M   5
M      "  54,  !A<G=R+3(P,C Q,# W7W!R92YX;6Q02P$"% ,4    "  /
MB$E14D?WA&03  !,GP  %               @ &8$0  87)W<BTX:U\R,#(P
M,3 P-RYH=&U02P$"% ,4    "  /B$E1C5/>CP(A  !&SP  $0
M    @ $N)0  87)W<BUE>#DY,5\S-"YH=&U02P4&      4 !0!& 0  7T8
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
